These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

977 related items for PubMed ID: 25455765

  • 1. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
    Mezghrani O, Tang Y, Ke X, Chen Y, Hu D, Tu J, Zhao L, Bourkaib N.
    Int J Pharm; 2015 Jan 30; 478(2):553-68. PubMed ID: 25455765
    [Abstract] [Full Text] [Related]

  • 2. GE11 peptide modified and reduction-responsive hyaluronic acid-based nanoparticles induced higher efficacy of doxorubicin for breast carcinoma therapy.
    Hu D, Mezghrani O, Zhang L, Chen Y, Ke X, Ci T.
    Int J Nanomedicine; 2016 Jan 30; 11():5125-5147. PubMed ID: 27785019
    [Abstract] [Full Text] [Related]

  • 3. Glycyrrhetinic acid-graft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs.
    Zhang L, Yao J, Zhou J, Wang T, Zhang Q.
    Int J Pharm; 2013 Jan 30; 441(1-2):654-64. PubMed ID: 23117024
    [Abstract] [Full Text] [Related]

  • 4. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y, Zhang J, Cheng R, Deng C, Meng F, Xie F, Zhong Z.
    J Control Release; 2015 May 10; 205():144-54. PubMed ID: 25596560
    [Abstract] [Full Text] [Related]

  • 5. Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy.
    Guo H, Lai Q, Wang W, Wu Y, Zhang C, Liu Y, Yuan Z.
    Int J Pharm; 2013 Jul 15; 451(1-2):1-11. PubMed ID: 23618965
    [Abstract] [Full Text] [Related]

  • 6. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
    Qi WW, Yu HY, Guo H, Lou J, Wang ZM, Liu P, Sapin-Minet A, Maincent P, Hong XC, Hu XM, Xiao YL.
    Mol Pharm; 2015 Mar 02; 12(3):675-83. PubMed ID: 25584860
    [Abstract] [Full Text] [Related]

  • 7. Hyaluronic acid ion-pairing nanoparticles for targeted tumor therapy.
    Li W, Yi X, Liu X, Zhang Z, Fu Y, Gong T.
    J Control Release; 2016 Mar 10; 225():170-82. PubMed ID: 26826304
    [Abstract] [Full Text] [Related]

  • 8. pH-Responsive Hyaluronic Acid-Based Mixed Micelles for the Hepatoma-Targeting Delivery of Doxorubicin.
    Wu JL, Tian GX, Yu WJ, Jia GT, Sun TY, Gao ZQ.
    Int J Mol Sci; 2016 Mar 30; 17(4):364. PubMed ID: 27043540
    [Abstract] [Full Text] [Related]

  • 9. Enhanced delivery of doxorubicin to the liver through self-assembled nanoparticles formed via conjugation of glycyrrhetinic acid to the hydroxyl group of hyaluronic acid.
    Wang X, Gu X, Wang H, Yang J, Mao S.
    Carbohydr Polym; 2018 Sep 01; 195():170-179. PubMed ID: 29804965
    [Abstract] [Full Text] [Related]

  • 10. A54 Peptide Modified and Redox-Responsive Glucolipid Conjugate Micelles for Intracellular Delivery of Doxorubicin in Hepatocarcinoma Therapy.
    Liu N, Tan Y, Hu Y, Meng T, Wen L, Liu J, Cheng B, Yuan H, Huang X, Hu F.
    ACS Appl Mater Interfaces; 2016 Dec 07; 8(48):33148-33156. PubMed ID: 27934140
    [Abstract] [Full Text] [Related]

  • 11. Insight into the role of dual-ligand modification in low molecular weight heparin based nanocarrier for targeted delivery of doxorubicin.
    Du H, Liu M, Yu A, Ji J, Zhai G.
    Int J Pharm; 2017 May 15; 523(1):427-438. PubMed ID: 28359815
    [Abstract] [Full Text] [Related]

  • 12. Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA.
    Chen F, Zhang J, He Y, Fang X, Wang Y, Chen M.
    Biomater Sci; 2016 Jan 15; 4(1):167-82. PubMed ID: 26484363
    [Abstract] [Full Text] [Related]

  • 13. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X, Chen Q, Li Y, Tang H, Liu W, Yang X.
    Eur J Pharm Biopharm; 2015 Jun 15; 93():27-36. PubMed ID: 25770771
    [Abstract] [Full Text] [Related]

  • 14. Glycyrrhetinic acid-conjugated polymeric prodrug micelles co-delivered with doxorubicin as combination therapy treatment for liver cancer.
    Yang T, Lan Y, Cao M, Ma X, Cao A, Sun Y, Yang J, Li L, Liu Y.
    Colloids Surf B Biointerfaces; 2019 Mar 01; 175():106-115. PubMed ID: 30529816
    [Abstract] [Full Text] [Related]

  • 15. Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation.
    Han X, Li Z, Sun J, Luo C, Li L, Liu Y, Du Y, Qiu S, Ai X, Wu C, Lian H, He Z.
    J Control Release; 2015 Jan 10; 197():29-40. PubMed ID: 25449802
    [Abstract] [Full Text] [Related]

  • 16. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
    Gupta B, Poudel BK, Ruttala HB, Regmi S, Pathak S, Gautam M, Jin SG, Jeong JH, Choi HG, Ku SK, Yong CS, Kim JO.
    Acta Biomater; 2018 Oct 15; 80():364-377. PubMed ID: 30201431
    [Abstract] [Full Text] [Related]

  • 17. Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.
    Pranatharthiharan S, Patel MD, Malshe VC, Pujari V, Gorakshakar A, Madkaikar M, Ghosh K, Devarajan PV.
    Drug Deliv; 2017 Nov 15; 24(1):20-29. PubMed ID: 28155331
    [Abstract] [Full Text] [Related]

  • 18. Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy.
    Zhang C, Wang W, Liu T, Wu Y, Guo H, Wang P, Tian Q, Wang Y, Yuan Z.
    Biomaterials; 2012 Mar 15; 33(7):2187-96. PubMed ID: 22169820
    [Abstract] [Full Text] [Related]

  • 19. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
    Zhang F, Jia Y, Zheng X, Shao D, Zhao Y, Wang Z, Dawulieti J, Liu W, Sun M, Sun W, Pan Y, Cui L, Wang Y, He K, Zhang M, Li J, Dong WF, Chen L.
    Acta Biomater; 2019 Dec 15; 100():352-364. PubMed ID: 31563690
    [Abstract] [Full Text] [Related]

  • 20. Bile acid-conjugated chondroitin sulfate A-based nanoparticles for tumor-targeted anticancer drug delivery.
    Lee JY, Chung SJ, Cho HJ, Kim DD.
    Eur J Pharm Biopharm; 2015 Aug 15; 94():532-41. PubMed ID: 26149228
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.